Literature DB >> 18160472

Kallmann's syndrome: a comparison of the reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations.

Sylvie Salenave1, Philippe Chanson, Hélène Bry, Michel Pugeat, Sylvie Cabrol, Jean Claude Carel, Arnaud Murat, Pierre Lecomte, Sylvie Brailly, Jean-Pierre Hardelin, Catherine Dodé, Jacques Young.   

Abstract

CONTEXT: Kallmann's syndrome (KS) is a genetically heterogeneous disorder consisting of congenital hypogonadotropic hypogonadism (CHH) with anosmia or hyposmia.
OBJECTIVE: Our objective was to compare the reproductive phenotypes of men harboring KAL1 and FGFR1/KAL2 mutations. DESIGN AND PATIENTS: We studied the endocrine features reflecting gonadotropic-testicular axis function in 39 men; 21 had mutations in KAL1 and 18 in FGFR1/KAL2, but none had additional mutations in PROK-2 or PROKR-2 genes.
RESULTS: Puberty failed to occur in the patients with KAL1 mutations, all of whom had complete CHH. Three patients with FGFR1/KAL2 mutations had normal puberty, were eugonadal, and had normal testosterone and gonadotropin levels. Cryptorchidism was more frequent (14 of 21 vs. 3 of 15; P<00.1) and testicular volume (2.4+/-1.1 vs. 5.4+/-2.4 ml; P<0.001) was smaller in CHH subjects with KAL1 mutations than in subjects with FGFR1/KAL2 mutations. The mean basal plasma FSH level (0.72+/-0.47 vs. 1.48+/-0.62 IU/liter; P<0.05), serum inhibin B level (19.3+/-10.6 vs. 39.5+/-19.3 pg/ml; P<0.005), basal LH plasma level (0.57+/-0.54 vs. 1.0+/-0.6 IU/liter; P<0.01), and GnRH-stimulated LH plasma level (1.2+/-1.0 vs. 4.1+/-3.5 IU/liter; P<0.01) were significantly lower in the subjects with KAL1 mutations. LH pulsatility was studied in 13 CHH subjects with KAL1 mutations and seven subjects with FGFR1/KAL2 mutations; LH secretion was nonpulsatile in all the subjects, but mean LH levels were lower in those with KAL1 mutations.
CONCLUSION: KAL1 mutations result in a more severe reproductive phenotype than FGFR1/KAL2 mutations. The latter are associated with a broader spectrum of pubertal development and with less severe impairment of gonadotropin secretion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160472     DOI: 10.1210/jc.2007-1168

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  GnRH signaling, the gonadotrope and endocrine control of fertility.

Authors:  Stuart P Bliss; Amy M Navratil; Jianjun Xie; Mark S Roberson
Journal:  Front Neuroendocrinol       Date:  2010-05-06       Impact factor: 8.606

Review 2.  The role of prokineticins in the pathogenesis of hypogonadotropic hypogonadism.

Authors:  Ana Paula Abreu; Ursula B Kaiser; Ana Claudia Latronico
Journal:  Neuroendocrinology       Date:  2010-05-21       Impact factor: 4.914

Review 3.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

4.  Clinical assessment and genomic landscape of a consanguineous family with three Kallmann syndrome descendants.

Authors:  Shi-Lin Zhang; Yan-Ping Tang; Tao Wang; Jun Yang; Ke Rao; Ling-Yun Zhao; Wen-Zhen Zhu; Xiang-Hu Meng; Shao-Gang Wang; Ji-Hong Liu; Wei-Min Yang; Zhang-Qun Ye
Journal:  Asian J Androl       Date:  2010-11-01       Impact factor: 3.285

Review 5.  The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism.

Authors:  Suzy D C Bianco; Ursula B Kaiser
Journal:  Nat Rev Endocrinol       Date:  2009-08-25       Impact factor: 43.330

Review 6.  Isolated GnRH deficiency: a disease model serving as a unique prism into the systems biology of the GnRH neuronal network.

Authors:  Ravikumar Balasubramanian; William F Crowley
Journal:  Mol Cell Endocrinol       Date:  2011-07-12       Impact factor: 4.102

7.  Fibroblast growth factor 2 regulates activity and gene expression of human post-mitotic excitatory neurons.

Authors:  Shweta Gupta; Tanya M-Redmond; Fan Meng; Andrew Tidball; Huda Akil; Stanley Watson; Jack M Parent; Michael Uhler
Journal:  J Neurochem       Date:  2017-12-27       Impact factor: 5.372

8.  Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes.

Authors:  Flavia Amanda Costa-Barbosa; Ravikumar Balasubramanian; Kimberly W Keefe; Natalie D Shaw; Nada Al-Tassan; Lacey Plummer; Andrew A Dwyer; Cassandra L Buck; Jin-Ho Choi; Stephanie B Seminara; Richard Quinton; Dorota Monies; Brian Meyer; Janet E Hall; Nelly Pitteloud; William F Crowley
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

9.  Kallmann syndrome.

Authors:  Catherine Dodé; Jean-Pierre Hardelin
Journal:  Eur J Hum Genet       Date:  2008-11-05       Impact factor: 4.246

10.  Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development.

Authors:  Kahina Boukari; Geri Meduri; Sylvie Brailly-Tabard; Jean Guibourdenche; Maria Luisa Ciampi; Nathalie Massin; Laetitia Martinerie; Jean-Yves Picard; Rodolfo Rey; Marc Lombès; Jacques Young
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.